Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Increase in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totaling 46,010 shares, an increase of 97.4% from the April 15th total of 23,312 shares. Based on an average daily trading volume, of 31,445 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.9% of the company’s stock are short sold.

Neuphoria Therapeutics Price Performance

Neuphoria Therapeutics stock traded down $0.01 during mid-day trading on Monday, reaching $4.72. 38,171 shares of the company traded hands, compared to its average volume of 30,753. Neuphoria Therapeutics has a fifty-two week low of $3.64 and a fifty-two week high of $21.40. The company has a market capitalization of $25.44 million, a price-to-earnings ratio of -0.43 and a beta of 0.72. The firm’s fifty day moving average is $4.72 and its two-hundred day moving average is $4.38.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.47. As a group, equities research analysts predict that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $21.00.

Institutional Trading of Neuphoria Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC acquired a new stake in Neuphoria Therapeutics during the 4th quarter valued at approximately $57,000. Ikarian Capital LLC acquired a new stake in Neuphoria Therapeutics during the 4th quarter valued at approximately $184,000. Geode Capital Management LLC lifted its stake in Neuphoria Therapeutics by 33.3% during the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after acquiring an additional 4,325 shares during the period. Persistent Asset Partners Ltd lifted its stake in Neuphoria Therapeutics by 173.1% during the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares during the period. Finally, Diadema Partners LP lifted its stake in Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after acquiring an additional 28,548 shares during the period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.